ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,064.20
      0.91%
      US Tech 100
      17,178.00
      1.88%
      Dow Jones
      38,225.66
      0.85%
      Brent Oil
      83.835
      0.25%
      Bitcoin
      59,534.01
      0.70%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Entera Bio Ltd (ENTX)

      7. Entera Bio Ltd (ENTX) News

      ENTX

      Entera Bio (ENTX)

      Entera Bio Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ENTX
      DateTimeSourceHeadlineSymbolCompany
      2:07PMiHub NewswireFeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
      04/08/20248:30AMGlobeNewswire Inc.Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchNASDAQ:ENTXEntera Bio Ltd
      03/26/20248:30AMGlobeNewswire Inc.Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsNASDAQ:ENTXEntera Bio Ltd
      03/20/20248:00AMGlobeNewswire Inc.Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeNASDAQ:ENTXEntera Bio Ltd
      03/08/20244:25PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ENTXEntera Bio Ltd
      03/08/20244:12PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ENTXEntera Bio Ltd
      03/08/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      03/08/20244:05PMGlobeNewswire Inc.Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
      03/04/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      03/04/20248:30AMGlobeNewswire Inc.Entera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:ENTXEntera Bio Ltd
      02/15/20245:10PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ENTXEntera Bio Ltd
      02/15/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENTXEntera Bio Ltd
      02/14/20246:05AMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ENTXEntera Bio Ltd
      02/02/20244:19PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      02/02/20244:17PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENTXEntera Bio Ltd
      01/30/20248:30AMGlobeNewswire Inc.Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ENTXEntera Bio Ltd
      01/16/20248:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/11/20246:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20246:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20244:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20244:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      01/03/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      01/02/20245:19PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ENTXEntera Bio Ltd
      12/27/20238:27AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
      12/26/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
      12/26/20238:00AMGlobeNewswire Inc.Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025NASDAQ:ENTXEntera Bio Ltd
      11/29/20238:30AMGlobeNewswire Inc.Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide PlatformNASDAQ:ENTXEntera Bio Ltd
      11/14/20237:30AMGlobeNewswire Inc.Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in DevelopmentNASDAQ:ENTXEntera Bio Ltd
      11/09/20232:30PMGlobeNewswire Inc.Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for OsteoporosisNASDAQ:ENTXEntera Bio Ltd
       Showing the most relevant articles for your search:NASDAQ:ENTX